Coronavirus vaccine approved for use in children

6 May 2021

Health Canada has approved a broader use of Comirnaty, the coronavirus vaccine from BioNTech (Nasdaq: BNTX) and Pfizer (NYSE: PFE), to include 12 to 15 year olds.

The decision from the Canadian medicines regulator marks a key milestone for the use of vaccines against COVID-19, at a time when rates of infection continue to rise globally.

The US Food and Drug Administration is also expected to provide a decision on broadening the label for Comirnaty this week, with the firm providing supportive data from a Phase III trial enrolling 2,260 adolescents.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK